European Archives - European Medical Journal

Interview: Nuru Noor

The original trial focused on sustained remission, including clinical and biochemical remission…

Takeda R&D head Andy Plump to retire after a decade

Andy Plump, the research and development chief who overhauled Takeda’s pipeline over more than a decade, will retire in June 2027.

Heart Disease Prevention Targets Missed Across Europe - EMJ

Heart Disease Prevention Targets Missed Across Europe

Most patients with coronary heart disease across Europe are missing recommended prevention targets, with major gaps in risk-factor control and cardiac rehabilitation.

Hydroxychloroquine Linked to Atherosclerotic Risk in SLE - EMJ

Hydroxychloroquine Levels Predict Atherosclerotic Risk in SLE

A prospective cohort study of 248 adults with SLE linked low hydroxychloroquine blood levels and poor adherence to higher predicted cardiovascular risk.

Hereditary Hypotrichosis Genetic Patterns Identified - EMJ

Hereditary Hypotrichosis Shows Distinct Genetic Patterns

A Chinese multicentre cohort identified 11 causative genes and distinct genotype–phenotype patterns in non-syndromic hereditary hypotrichosis.

Colorectal Cancer Super Enhancer Findings - EMJ

Colorectal Cancer Reveals New Super Enhancer Circuitry

A core MYC, ETS2 and FOXP1 regulatory circuitry regulated super enhancer activity in colorectal cancer and highlighted a distal enhancer driving LGR5 activation.

Brain Aneurysms May Be Twice as Common as Thought - EMJ

Brain Aneurysms May Be Twice as Common as Previously Thought

Brain aneurysm prevalence has more than doubled in two decades, according to a major analysis of over 316,000 people.

Lungs shape made from yellow paper on a palm old woman on a blue background

AZ's COPD drug cuts flare-ups in two phase 3 trials

AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in 2027 now possible.

New MASH Drug Reduces Liver Fat in Phase 2 Trial

New MASH Drug Reduces Liver Fat in Phase 2 Trial

An experimental drug significantly reduced liver fat after 12 weeks in adults with MASH in a phase 2 clinical trial.

Where is the Future of Diabetes Treatment Heading? Interview with David M. Nathan

The major studies I have participated in have all been collegial, collaborative efforts. I helped lead some of…